挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

比利時(shí)聯(lián)合化工集團(tuán)(UCB)    
比利時(shí)聯(lián)合化工集團(tuán)(UCB)是比利時(shí)一家大型醫(yī)藥化工企業(yè)。公司創(chuàng)立于1928年，總部設(shè)在布魯塞爾市，目前集團(tuán)下屬共有150余家子公司，分布在世界各地，共有雇員近萬名。

比利時(shí)聯(lián)合化工企業(yè)有限公司(UCB)是一家具有百年悠久歷史的跨國(guó)公司，主要業(yè)務(wù)涉及醫(yī)藥、特種化工和薄膜。1995年中國(guó)代表處在上海正式成立。1997年中國(guó)藥品部成立，著重從事處方藥品的開發(fā)、生產(chǎn)和銷售，特別在開發(fā)研究上的大量投入，使得產(chǎn)品在其涉足的領(lǐng)域,包括變態(tài)反應(yīng)系統(tǒng)、中樞神經(jīng)系統(tǒng)和心血管系統(tǒng)保持領(lǐng)先地位。尤其是UCB皇冠上兩顆熠熠生輝的明珠－仙特明和腦復(fù)康。它們被歐美、日本等一百多個(gè)國(guó)家批準(zhǔn)銷售，受到了全球醫(yī)藥界的矚目。

集團(tuán)的業(yè)務(wù)分為三大部分：藥品部、化工部和薄膜部。2001年集團(tuán)總營(yíng)業(yè)額為24.75億歐元，比上年增加了12%，凈利潤(rùn)3.18億歐元，增長(zhǎng)了18%。其中藥品部營(yíng)業(yè)額達(dá)14.27億歐元，化工部營(yíng)業(yè)額6.52億歐元，薄膜部營(yíng)業(yè)額3.96億歐元。該集團(tuán)95%的產(chǎn)品銷往國(guó)外，公司的主要業(yè)務(wù)在歐洲，銷售額占55%，美國(guó)的銷售額占24%，亞洲占19%。

集團(tuán)以創(chuàng)新和全球化作為自己的經(jīng)營(yíng)戰(zhàn)略，每年投入大量的研究開發(fā)費(fèi)用，生產(chǎn)自己開發(fā)的新產(chǎn)品，并盡快占領(lǐng)國(guó)際市場(chǎng)，2000年集團(tuán)研發(fā)費(fèi)用達(dá)1.82億歐元。在經(jīng)營(yíng)管理方面，集團(tuán)總部負(fù)責(zé)產(chǎn)品的研究開發(fā)、人員的培訓(xùn)以及確定戰(zhàn)略目標(biāo)，各子公司則擁有較大的自主權(quán)，可根據(jù)當(dāng)?shù)氐氖袌?chǎng)發(fā)展變化制定相應(yīng)的銷售戰(zhàn)略。這種靈活的組織形式，使集團(tuán)有很強(qiáng)的應(yīng)變能力，并能隨時(shí)掌握市場(chǎng)的脈搏。該集團(tuán)始終堅(jiān)持生產(chǎn)銷售附加值高的產(chǎn)品。他們所涉足的領(lǐng)域往往在世界上處于領(lǐng)先地位。如他們生產(chǎn)銷售的抗過敏藥ZYRTEC，是歐洲市場(chǎng)上銷售最多的抗過敏藥。他們生產(chǎn)銷售的調(diào)節(jié)人體大腦活動(dòng)的藥物NOOTROPIL也是世界著名的藥物之一。此外，其化工部生產(chǎn)的RADCURE樹脂，年產(chǎn)量達(dá)6萬多噸，為世界第一大生產(chǎn)商，占領(lǐng)了世界市場(chǎng)35%的份額；CRYLCOAT樹脂，年產(chǎn)量達(dá)9萬多噸，為世界第一大生產(chǎn)商，占領(lǐng)了世界市場(chǎng)30%的份額；再如甲胺及其產(chǎn)品，年產(chǎn)量達(dá)26萬多噸，占領(lǐng)了世界市場(chǎng)20%的份額。薄膜部生產(chǎn)的兩大類產(chǎn)品也在世界市場(chǎng)上占有重要地位。如聚丙烯雙向膜PROPAFILM，為世界第六大生產(chǎn)商，年產(chǎn)量為7.5萬噸。該集團(tuán)還是世界最大玻璃紙生產(chǎn)商，年產(chǎn)玻璃紙6萬噸，用于各種包裝。

比利時(shí)聯(lián)合化工集團(tuán)積極發(fā)展與中國(guó)的業(yè)務(wù)聯(lián)系，并在中國(guó)投資了1000萬美元，在上海奉賢與上海鳳凰自行車集團(tuán)合資建立了樹脂生產(chǎn)廠和飼料廠各一家。

Scientific and technological advances have created a new opportunity to address the complex interconnections of severe diseases much more effectively.

We call this opportunity ‘the next generation biopharma leader'. And we are rapidly bringing it to life, it is about:

Connecting science in new waysBy integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.

The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition.Cimzia?, our most advanced New Biological Entity (NBE), targeted at Crohn's disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.Connecting peopleIn a knowledge- and ideas-based industry like ours, human capital is the lifeblood of success. To unlock the creative potential of our global team of over 10,000 staff and our 30-plus partners, we are creating a networked, cross-functional organisation.

UCB People, an innovative intranet tool, links our knowledge and skills. Our virtual R&D collaboration platform, based on the principles of Wikipedia, is another example.Multi-disciplinary teams are working on all development projects, including members of R&D, supply chain and sales, as well as partners and patients...Connecting patientsSevere diseases, such as Epilepsy, Crohn's or Parkinson's, tend to be "silent diseases" - sufferers are often socially stigmatised and reluctant to share their experiences and insights. To overcome this problem, we are creating novel and personal ways for patients and their families to connect, virtually and live, with each other, us, our partners and opinion formers.

The "CrohnsandMe.com" community is one such exampleThe sponsorship of a Pearl Jam concert demonstrates our commitment to raise awareness of severe diseasesPatients and their families are regularly invited to discuss the daily realities of their diseases with our staff, partners and key opinion informers - providing invaluable insights.
A global biopharma focused on severe diseases
with operations in more than 40 countries and global revenue of €3.6 billion in 2008A leader in allergy and epilepsy
with 11 large and small molecules in the pipeline, spanning 13 diseases, from Crohn's and Parkinson's to multiple sclerosis.A leader in antibody research
supported by proprietary chemistry and over 30 major R&D partners.